Key result
Mitral TEER improves concomitant tricuspid regurgitation in ~33% of patients.
Why the study?
Correction of mitral regurgitation does not consistently reverse concomitant tricuspid regurgitation, and the optimal timing and clinical benefit of combined transcatheter edge-to-edge repair remain uncertain.
Does combined mitral and tricuspid transcatheter edge-to-edge repair improve clinical outcomes compared to isolated mitral transcatheter edge-to-edge repair in patients with concomitant mitral and tricuspid regurgitation?
Does combined mitral and tricuspid transcatheter edge-to-edge repair improve clinical outcomes compared to isolated mitral transcatheter edge-to-edge repair in patients with concomitant mitral and tricuspid regurgitation?
This narrative review synthesizes current evidence on combined mitral and tricuspid TEER, noting that TR improves in only about one-third of patients after isolated M-TEER and highlighting the need for randomized trials to determine optimal bivalvular timing and clinical benefit.
Answers are grounded in this paper and cite their sources.
Combined repair should not yet change practice; leaves open optimal patient selection and timing pending randomized trials.
Concomitant mitral regurgitation (MR) and tricuspid regurgitation (TR) constitute an interconnected multivalvular syndrome, but correction of MR does not consistently reverse TR. This narrative review examines TR evolution after mitral transcatheter edge-to-edge repair (M-TEER), patient selection, imaging, procedural strategies, and evidence for treatment of both valves. Combined TEER denotes bivalvular treatment, performed during the same session or in stages. Observational cohorts report TR improvement in approximately one-third of broadly selected patients after M-TEER, with substantial variation according to baseline severity, response definition, and follow-up. Persistent or new-onset TR is associated with adverse outcomes; these associations do not establish that subsequent tricuspid intervention improves survival. Comparative registries suggest potential clinical benefit from combined treatment, whereas uncontrolled series primarily establish technical feasibility in selected patients at experienced centers. Treatment timing remains uncertain because randomized comparisons of isolated, same-session, and staged strategies are unavailable. The proposed Heart Team framework integrates lesion-specific indications, anatomical suitability, anticipated TR reversibility, physiological reserve, and patient goals. It is an unvalidated discussion aid rather than a treatment recommendation. Randomized strategy trials are needed to establish incremental clinical benefit, comparative safety, and optimal timing.
No takes yet. Share an insight, caveat, or question.
Papadopoulos et al. (2026) conducted a review in Concomitant mitral regurgitation (MR) and tricuspid regurgitation (TR). Combined mitral and tricuspid transcatheter edge-to-edge repair (TEER) vs. Isolated mitral transcatheter edge-to-edge repair (M-TEER), same-session vs staged strategies was evaluated on Tricuspid regurgitation evolution and clinical outcomes after M-TEER or combined TEER. Mitral transcatheter edge-to-edge repair improves concomitant tricuspid regurgitation in approximately one-third of patients, while combined bivalvular TEER shows feasibility in registries.
Synapse has enriched 10 related papers. Consider them for comparative context: